• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Magna-Lab ceases manufacturing

Article

Financially troubled Magna-Lab has ceased operations and has vacated its Edgewood, NY, manufacturing and office facility. Negotiations are under way to sell the developer of niche MRI scanners, according to vice president of marketing John Haytaian.The

Financially troubled Magna-Lab has ceased operations and has vacated its Edgewood, NY, manufacturing and office facility. Negotiations are under way to sell the developer of niche MRI scanners, according to vice president of marketing John Haytaian.

The company's status began unraveling this year when manufacturing operations were halted and 16 of 21 employees were laid off at the end of March, Haytaian said (SCAN 4/2/97). Most of the company's remaining business is handled by CEO Lawrence Minkoff and CFO Kenneth Riscica. Minkoff did not respond to phone calls.

According to a report filed with the Securities and Exchange Commission in April, the company adopted a restructuring plan that calls for the elimination of production, marketing, and some system engineering capability by strengthening its existing relationship with Elscint Cryomagnetics. Magna-Lab was notified by Elscint that if the Elscint proposal was not finalized by May 30, Elscint could seek to terminate the relationship. The two companies signed an agreement in June 1996, giving Elscint the exclusive right to market Magna-Lab's Magna-SL dedicated extremity MR scanner in certain international markets. Elscint was also expected to manufacture the 0.4-tesla system at its Fort Collins, CO, plant. Negotiations to finalize details of the agreement continued into March.

The Elscint agreement was still in place as of June 20, according to Haytaian. But more discussion is needed to work out how the relationship will proceed given that Magna-Lab is no longer manufacturing.

"Things are different in that Magna-Lab may take a different form going into the future," he said.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.